carried out a literature review on currently available novel HER2-targeted substances influencing BMs in patients with breast cancer and summarized that, aside from anti-HER2 monoclonal antibodies, tyrosine kinase inhibitors and antibody–drug conjugates have exhibited antineoplastic intracranial activity, either by affecting established central nervous system metastases or by delaying the time until development of subsequent BMs. The gene discussed is ERBB2; the disease is breast carcinoma.